Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain.

Kaufmann D, West PJ, Smith MD, Yagen B, Bialer M, Devor M, White HS, Brennan KC.

Pharmacol Res. 2017 Mar;117:129-139. doi: 10.1016/j.phrs.2016.11.030. Epub 2016 Nov 24.

2.

sec-Butylpropylacetamide (SPD) has antimigraine properties.

Kaufmann D, Bates EA, Yagen B, Bialer M, Saunders GH, Wilcox K, White HS, Brennan KC.

Cephalalgia. 2016 Sep;36(10):924-35. doi: 10.1177/0333102415612773. Epub 2015 Nov 13.

3.

The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus.

Shekh-Ahmad T, Mawasi H, McDonough JH, Yagen B, Bialer M.

Epilepsy Behav. 2015 Aug;49:298-302. doi: 10.1016/j.yebeh.2015.04.012. Epub 2015 May 13. Review.

PMID:
25979572
4.

Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential.

Shekh-Ahmad T, Hen N, Yagen B, McDonough JH, Finnell RH, Wlodarczyk BJ, Bialer M.

Epilepsia. 2014 Feb;55(2):353-61. doi: 10.1111/epi.12480. Epub 2013 Dec 6.

5.

Teratology study of amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide in NMRI mice.

Onishi Y, Okada A, Noyori H, Okamura A, Hen N, Yagen B, Bialer M, Fujiwara M.

Birth Defects Res B Dev Reprod Toxicol. 2013 Aug;98(4):318-27. doi: 10.1002/bdrb.21068. Epub 2013 Aug 26.

PMID:
24039104
6.

Valnoctamide and sec-butyl-propylacetamide (SPD) for acute seizures and status epilepticus.

Shekh-Ahmad T, Hen N, McDonough JH, Yagen B, Bialer M.

Epilepsia. 2013 Sep;54 Suppl 6:99-102. doi: 10.1111/epi.12290.

7.

Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.

Hen N, Shekh-Ahmad T, Yagen B, McDonough JH, Finnell RH, Wlodarczyk B, Bialer M.

J Med Chem. 2013 Aug 22;56(16):6467-77. doi: 10.1021/jm4007565. Epub 2013 Aug 7.

PMID:
23879329
8.

Valproic acid derivatives signal for apoptosis and repair in vitro.

Neuman MG, Nanau RM, Shekh-Ahmad T, Yagen B, Bialer M.

Clin Biochem. 2013 Oct;46(15):1532-7. doi: 10.1016/j.clinbiochem.2013.07.003. Epub 2013 Jul 15.

PMID:
23868021
9.

Derivatives of valproic acid are active against pentetrazol-induced seizures in immature rats.

MareŇ° P, Kubov√° H, Hen N, Yagen B, Bialer M.

Epilepsy Res. 2013 Sep;106(1-2):64-73. doi: 10.1016/j.eplepsyres.2013.06.001. Epub 2013 Jun 28.

PMID:
23815889
10.

A comparative electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus.

Pouliot W, Bialer M, Hen N, Shekh-Ahmad T, Kaufmann D, Yagen B, Ricks K, Roach B, Nelson C, Dudek FE.

Neuroscience. 2013 Feb 12;231:145-56. doi: 10.1016/j.neuroscience.2012.11.005. Epub 2012 Nov 14.

PMID:
23159312
11.

Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates.

Hen N, Bialer M, Yagen B.

J Med Chem. 2012 Mar 22;55(6):2835-45. doi: 10.1021/jm201751x. Epub 2012 Mar 7.

PMID:
22339381
12.

A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage.

White HS, Alex AB, Pollock A, Hen N, Shekh-Ahmad T, Wilcox KS, McDonough JH, Stables JP, Kaufmann D, Yagen B, Bialer M.

Epilepsia. 2012 Jan;53(1):134-46. doi: 10.1111/j.1528-1167.2011.03338.x. Epub 2011 Dec 9. Erratum in: Epilepsia. 2012 Feb;53(2):397.

13.

Design and pharmacological activity of glycinamide and N-methoxy amide derivatives of analogs and constitutional isomers of valproic acid.

Pessah N, Yagen B, Hen N, Shimshoni JA, Wlodarczyk B, Finnell RH, Bialer M.

Epilepsy Behav. 2011 Nov;22(3):461-8. doi: 10.1016/j.yebeh.2011.08.026. Epub 2011 Sep 29.

PMID:
21959082
14.

The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium.

Chang P, Orabi B, Deranieh RM, Dham M, Hoeller O, Shimshoni JA, Yagen B, Bialer M, Greenberg ML, Walker MC, Williams RS.

Dis Model Mech. 2012 Jan;5(1):115-24. doi: 10.1242/dmm.008029. Epub 2011 Aug 29.

15.

Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII, and XIV.

Hen N, Bialer M, Yagen B, Maresca A, Aggarwal M, Robbins AH, McKenna R, Scozzafava A, Supuran CT.

J Med Chem. 2011 Jun 9;54(11):3977-81. doi: 10.1021/jm200209n. Epub 2011 May 9.

PMID:
21506569
16.

Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid.

Pessah N, Kaufmann D, Yagen B, Hen N, Wlodarczyk B, Finnell RH, Bialer M.

Epilepsia. 2010 Oct;51(10):1944-53. doi: 10.1111/j.1528-1167.2010.02684.x.

17.

Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.

Hen N, Bialer M, Wlodarczyk B, Finnell RH, Yagen B.

J Med Chem. 2010 May 27;53(10):4177-86. doi: 10.1021/jm100170w.

PMID:
20420384
18.

Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid.

Kaufmann D, Yagen B, Minert A, Wlodarczyk B, Finnell RH, Schurig V, Devor M, Bialer M.

Neuropharmacology. 2010 Jun;58(8):1228-36. doi: 10.1016/j.neuropharm.2010.03.004. Epub 2010 Mar 15.

PMID:
20230843
19.

Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.

Kaufmann D, Bialer M, Shimshoni JA, Devor M, Yagen B.

J Med Chem. 2009 Nov 26;52(22):7236-48. doi: 10.1021/jm901229s.

PMID:
19877649
20.

Anticonvulsant profile and teratogenic evaluation of potent new analogues of a valproic acid urea derivative in NMRI mice.

Okada A, Noyori H, Yagen B, Shimshoni JA, Bialer M, Fujiwara M.

Birth Defects Res B Dev Reprod Toxicol. 2009 Oct;86(5):394-401. doi: 10.1002/bdrb.20209.

PMID:
19830722
21.

Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): a chiral stereoisomer of valproic acid urea derivative.

Shimshoni JA, Yagen B, Wlodarczyk B, Finnell RH, Schurig V, Bialer M.

Epilepsia. 2010 Mar;51(3):323-32. doi: 10.1111/j.1528-1167.2009.02241.x. Epub 2009 Aug 8.

22.

Alpha-fluoro-2,2,3,3-tetramethylcyclopropanecarboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid.

Pessah N, Bialer M, Wlodarczyk B, Finnell RH, Yagen B.

J Med Chem. 2009 Apr 23;52(8):2233-42. doi: 10.1021/jm900017f.

PMID:
19296679
23.

Tetramethylcyclopropyl analogue of the leading antiepileptic drug, valproic acid: evaluation of the teratogenic effects of its amide derivatives in NMRI mice.

Okada A, Onishi Y, Yagen B, Shimshoni JA, Kaufmann D, Bialer M, Fujiwara M.

Birth Defects Res A Clin Mol Teratol. 2008 Sep;82(9):610-21. doi: 10.1002/bdra.20490.

PMID:
18671279
24.

Synthesis and anticonvulsant activity of aromatic tetramethylcyclopropanecarboxamide derivatives.

Shimshoni JA, Bialer M, Yagen B.

Bioorg Med Chem. 2008 Jun 1;16(11):6297-305. doi: 10.1016/j.bmc.2008.03.051. Epub 2008 Mar 23.

PMID:
18472270
25.

Anticonvulsant profile and teratogenicity of 3,3-dimethylbutanoylurea: a potential for a second generation drug to valproic acid.

Shimshoni JA, Yagen B, Pessah N, Wlodarczyk B, Finnell RH, Bialer M.

Epilepsia. 2008 Jul;49(7):1202-12. doi: 10.1111/j.1528-1167.2008.01624.x.

26.

Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide.

Kaufmann D, Yagen B, Minert A, Tal M, Devor M, Bialer M.

Neuropharmacology. 2008 Mar;54(4):699-707. doi: 10.1016/j.neuropharm.2007.11.020. Epub 2007 Dec 8.

PMID:
18201732
27.

Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid.

Shimshoni JA, Bialer M, Wlodarczyk B, Finnell RH, Yagen B.

J Med Chem. 2007 Dec 13;50(25):6419-27. Epub 2007 Nov 10.

PMID:
17994680
28.

Valproic Acid: second generation.

Bialer M, Yagen B.

Neurotherapeutics. 2007 Jan;4(1):130-7. Review.

PMID:
17199028
29.

The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior.

Shimshoni JA, Dalton EC, Jenkins A, Eyal S, Ewan K, Williams RS, Pessah N, Yagen B, Harwood AJ, Bialer M.

Mol Pharmacol. 2007 Mar;71(3):884-92. Epub 2006 Dec 13.

PMID:
17167030
30.

Anticonvulsant activity, neural tube defect induction, mutagenicity and pharmacokinetics of a new potent antiepileptic drug, N-methoxy-2,2,3,3-tetramethylcyclopropane carboxamide.

Sobol E, Yagen B, Lamb JG, White HS, Wlodarczyk BJ, Finnell RH, Bialer M.

Epilepsy Res. 2007 Jan;73(1):75-84. Epub 2006 Sep 25.

PMID:
16997532
31.

The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver.

Eyal S, Lamb JG, Smith-Yockman M, Yagen B, Fibach E, Altschuler Y, White HS, Bialer M.

Br J Pharmacol. 2006 Oct;149(3):250-60. Epub 2006 Aug 7.

32.

Preclinical evaluation of 2,2,3,3-tetramethylcyclopropanecarbonyl-urea, a novel, second generation to valproic acid, antiepileptic drug.

Sobol E, Yagen B, Steve White H, Wilcox KS, Lamb JG, Pappo O, Wlodarczyk BJ, Finnell RH, Bialer M.

Neuropharmacology. 2006 Sep;51(4):933-46. Epub 2006 Aug 4.

PMID:
16890251
33.

Teratology study of derivatives of tetramethylcyclopropyl amide analogues of valproic acid in mice.

Okada A, Onishi Y, Aoki Y, Yagen B, Sobol E, Bialer M, Fujiwara M.

Birth Defects Res B Dev Reprod Toxicol. 2006 Jun;77(3):227-33.

PMID:
16767757
34.

Efficacy of antiepileptic tetramethylcyclopropyl analogues of valproic acid amides in a rat model of neuropathic pain.

Winkler I, Sobol E, Yagen B, Steinman A, Devor M, Bialer M.

Neuropharmacology. 2005 Dec;49(8):1110-20. Epub 2005 Aug 1.

PMID:
16055160
35.

Pharmacokinetics and metabolism of a new potent antiepileptic drug, 2,2,3,3-tetramethycyclopropanecarbonylurea, in rats.

Sobol E, Yagen B, Winkler I, Britzi M, Gibson D, Bialer M.

Drug Metab Dispos. 2005 Oct;33(10):1538-46. Epub 2005 Jul 21.

PMID:
16037415
36.

Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain.

Winkler I, Blotnik S, Shimshoni J, Yagen B, Devor M, Bialer M.

Br J Pharmacol. 2005 Sep;146(2):198-208.

37.

Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives.

Eyal S, Yagen B, Shimshoni J, Bialer M.

Biochem Pharmacol. 2005 May 15;69(10):1501-8.

PMID:
15857614
39.

The activity of antiepileptic drugs as histone deacetylase inhibitors.

Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M.

Epilepsia. 2004 Jul;45(7):737-44.

40.

Metabolism of a new antiepileptic drug, N-methyl-tetramethylcyclopropanecarboxamide, and anticonvulsant activity of its metabolites.

Isoherranen N, Levy RH, Yagen B, Woodhead JH, White HS, Bialer M.

Epilepsy Res. 2004 Jan;58(1):1-12.

PMID:
15066669
41.

Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyl-oxo-pyrrolidine acetamide in a mouse model of teratogenicity.

Isoherranen N, Spiegelstein O, Bialer M, Zhang J, Merriweather M, Yagen B, Roeder M, Triplett AA, Schurig V, Finnell RH.

Epilepsia. 2003 Oct;44(10):1280-8.

42.

Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy.

Isoherranen N, White HS, Klein BD, Roeder M, Woodhead JH, Schurig V, Yagen B, Bialer M.

Pharm Res. 2003 Aug;20(8):1293-301.

PMID:
12948028
43.

Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice.

Isoherranen N, Yagen B, Spiegelstein O, Finnell RH, Merriweather M, Woodhead JH, Wlodarczyk B, White HS, Bialer M.

Br J Pharmacol. 2003 Jun;139(4):755-64.

44.

Gas chromatographic determination of novel valproyl taurinamide derivatives in mouse and dog plasma.

Isoherranen N, Yagen B, Spiegelstein O, Steinman A, Finnell RH, Bialer M.

J Chromatogr B Analyt Technol Biomed Life Sci. 2003 May 5;788(1):125-36.

PMID:
12668078
45.

New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?

Isoherranen N, Yagen B, Bialer M.

Curr Opin Neurol. 2003 Apr;16(2):203-11. Review.

PMID:
12644750
46.

Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents.

Isoherranen N, Yagen B, Woodhead JH, Spiegelstein O, Blotnik S, Wilcox KS, Finnell RH, Bennett GD, White HS, Bialer M.

Br J Pharmacol. 2003 Feb;138(4):602-13.

47.

Anticonvulsant profile and teratogenicity of N-methyl-tetramethylcyclopropyl carboxamide: a new antiepileptic drug.

Isoherranen N, White HS, Finnell RH, Yagen B, Woodhead JH, Bennett GD, Wilcox KS, Barton ME, Bialer M.

Epilepsia. 2002 Feb;43(2):115-26.

48.

Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs.

Isoherranen N, Yagen B, Soback S, Roeder M, Schurig V, Bialer M.

Epilepsia. 2001 Jul;42(7):825-30.

49.
50.

Enantioselective analysis of levetiracetam and its enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion trap mass spectrometric detection.

Isoherranen N, Roeder M, Soback S, Yagen B, Schurig V, Bialer M.

J Chromatogr B Biomed Sci Appl. 2000 Aug 18;745(2):325-32.

PMID:
11043751

Supplemental Content

Support Center